指南与共识乳房整形与再造

乳房重建围手术期抗雌激素治疗:系统综述与治疗建议

Perioperative Use of Antiestrogen Therapies in Breast Reconstruction: A Systematic Review and Treatment Recommendations.
指南 / 共识 · Ann Plast Surg · 2020-01-01

系统综述评估选择性雌激素受体调节剂(SERM)和芳香化酶抑制剂(AI)对乳房重建结局的影响。分析2581个皮瓣发现,术时使用SERM者皮瓣丢失率更高(P<0.001),AI不影响皮瓣丢失(P=0.11),但两者均增加供区并发症风险。建议术前停药1-2个半衰期。

要点

  • 术时使用SERM与皮瓣丢失风险增加相关,AI无此影响。
  • SERM和AI均与供区并发症风险升高相关。
  • 建议术前停用SERM 14-28天,AI 2-4天。

核心结论

  • 术时使用SERM的患者皮瓣丢失风险增加,使用SERM或AI的患者供区并发症率更高。
  • 证据支持术前停用SERM 1-2个半衰期(他莫昔芬14-28天)和AI 2-4天。

研究设计与样本

  • 系统综述,检索MEDLINE、PubMed和EBSCO Host数据库中关于SERM和AI对乳房重建影响的文献。
  • 共分析2581个皮瓣,纳入研究采用MINORS质量评分。

主要发现

  • 术时使用SERM者皮瓣完全丢失率高于未使用激素调节剂者(P<0.001)。
  • 同期使用AI不影响皮瓣丢失(P=0.11)。
  • SERM和AI均增加供区并发症风险(分别为P=0.0021和P<0.0001)。
  • 两种激素调节剂对皮瓣伤口并发症或静脉血栓栓塞事件率均无影响。

关键数值与推荐

  • 术前停用他莫昔芬14-28天(1-2个半衰期)。
  • 术前停用AI 2-4天(1-2个半衰期)。

临床怎么用

  • 乳房重建术前应评估患者是否使用SERM或AI,并考虑按半衰期停药以降低皮瓣丢失和供区并发症风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with hormone receptor-positive breast tumors receive hormonal therapy with either selective estrogen receptor modulators (SERMs) (eg, tamoxifen) or aromatase inhibitors (AIs) (eg, anastrozole) for 5 to 10 years. Patients are using these therapies frequently during breast reconstruction. Literature investigating the effects of hormonal modulators on breast reconstruction outcomes demonstrates conflicting results. We sought to perform a systematic evaluation to assess the effects of hormonal therapy on breast reconstruction outcomes and to guide perioperative management of antiestrogen therapies. METHODS: A MEDLINE, PubMed, and EBSCO Host search of articles regarding the effects of SERMs and AIs on breast reconstruction was performed. Outcomes evaluated included wound complications, total or partial flap loss, and thromboembolic events. Included studies were assigned Methodological Index for Nonrandomized Studies quality scores. RESULTS: A total of 2581 flaps were analyzed for complete loss: patients taking SERMs at the time of reconstruction had higher rates of flap loss compared with patients not taking hormone modulators (P < 0.001). Flap loss was not affected by concurrent AI use (P = 0.11). Both SERMs and AIs had an increased risk of donor site complications (P = 0.0021 and P < 0.0001, respectively). Neither hormone modulator had an effect on flap wound complications or venous thromboembolic event rates. CONCLUSIONS: Evidence indicates patients using SERMs at the time of operation are at an increased risk of flap loss and those taking either SERMs or AIs have higher rates of donor site complications. These findings support holding these medications for 1 to 2 half lives (tamoxifen, 14-28 days; AIs, 2-4 days) preoperatively.

来源:Ann Plast Surg,查看原文。版权归原作者所有。

引用

  1. Spera LJ, Cook JA, Dolejs S, et al. Perioperative Use of Antiestrogen Therapies in Breast Reconstruction: A Systematic Review and Treatment Recommendations. Ann Plast Surg. 2020. PMID: 32332390. doi:10.1097/SAP.0000000000002394

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。